Robotic gastric cancer surgery in a man with situs inversus totalis and no recurrence at 2.5 years

This gastric cancer diagnosis at a glance
- Subtype
- Adenocarcinoma
- Biomarkers
- HER2 (C-erbB-2) 2+
- Sex
- Male
- Treatment
- chemotherapy and surgery
- Outcome
- Cancer-Free / NED
Treatment course, step by step
- Received 2 cycles of neoadjuvant oxaliplatin plus S-1 chemotherapy.
- Underwent robotic distal gastrectomy with D2 lymph-node dissection and Billroth II reconstruction.
- Received 4 postoperative cycles of the same chemotherapy.
What happened, in summary
A 53-year-old man was admitted in December 2014 with upper-abdominal bloating. CT showed thickening of the distal stomach and enlarged nearby lymph nodes. Imaging also confirmed situs inversus totalis, meaning his internal organs were arranged in a mirror-image pattern. Endoscopy found a 6-cm antral tumor, and biopsy showed gastric adenocarcinoma with a HER2 (C-erbB-2) score of 2+.
Because of the tumor size and enlarged lymph nodes, he received 2 cycles of preoperative oxaliplatin plus S-1 chemotherapy. In February 2015, he underwent fully robotic distal gastrectomy with D2 lymph-node dissection and Billroth II reconstruction. The surgical team adapted the port placement and dissection to his reversed anatomy. Pathology showed residual gastric adenocarcinoma involving the stomach wall, with 4 of 5 lymph nodes along the greater curvature involved.
He recovered quickly, was discharged on the fifth postoperative day, and began postoperative chemotherapy one week later. He completed 4 additional cycles of the same regimen. Two and a half years after surgery, no recurrence had developed.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer